Medicare Part B Oral Chemotherapy Demo To Cover Tamoxifen and Thalidomide
This article was originally published in The Pink Sheet Daily
Executive Summary
In announcing the start of the demonstration project, CMS departs from earlier demo criteria by saying that tamoxifen qualifies as a “replacement” drug and thalidomide is covered because it has a pending supplemental NDA for an indication qualifying it for the project.
You may also be interested in...
Medicare Replacement Drug Demo
Schering-Plough's Temodar will not be covered under Medicare's replacement drug demonstration because it is already covered under Part B, a Centers for Medicare & Medicaid Services notice of correction published in the Aug. 27 Federal Register states.
Medicare Replacement Drug Demo
Schering-Plough's Temodar will not be covered under Medicare's replacement drug demonstration because it is already covered under Part B, a Centers for Medicare & Medicaid Services notice of correction published in the Aug. 27 Federal Register states.
Somavert, Mesnex Join Medicare Rx Demo
The Pfizer and Baxter products are part of an updated list of drugs that will be reimbursed under a Part B demonstration for oral substitutes of injectable drugs.